Early study shows Ebola vaccine to be safe

the Oncology Nurse Advisor take:

The Ad5-EBOV Ebola virus vaccine was proven safe in an early study in healthy adults in China, a new study published in the journal The Lancet has shown.

The Phase 1 study evaluated the safety of the vaccine in 120 healthy people in China's Jiangsu province. Participants received either a low dose or high dose of the vaccine, or placebo.

Participants were then monitored for over 28 days for any adverse events and an immune response. Results showed that no serious adverse events occurred and antibodies were significantly increased in participants.

Although the study did not demonstrate whether the immune response lasted longer than 28 days or whether a booster immunization would be needed, researchers say that the vaccine has potential.

Ad5-EBOV is not the only vaccination being studied to combat the Ebola virus, which has killed more 10,000 people since the beginning of 2014.

Other vaccines are currently in Phase III testing where they are being used in people at risk of infection in west Africa. The United Nations Ebola response team said this week that the Ebola outbreak should be gone by this summer.

The Ad5-EBOV Ebola virus vaccine was proven safe in an early study in healthy adults in China.

The latest in a string of candidate vaccines against the deadly Ebola virus was proven safe in an early trial in healthy adults in China, its developers said Wednesday.